| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/26/2011 | WO2010107939A3 Human immunodeficiency virus (hiv) -neutralizing antibodies |
| 05/26/2011 | WO2010103022A3 Oil-in-water adjuvanted influenza vaccine |
| 05/26/2011 | WO2007047579A3 A novel therapeutic target for protozoal diseases |
| 05/26/2011 | US20110126306 Circular Nucleic Acid Vectors, and Methods for Making and Using the Same |
| 05/26/2011 | US20110126301 Dendritic Cell Marker and Uses Thereof |
| 05/26/2011 | US20110124550 Thymosin beta 4 promotes wound repair |
| 05/26/2011 | US20110124016 Diagnosis and Treatment of Malignant Neoplasms |
| 05/26/2011 | US20110123702 Room temperature-curable polymers |
| 05/26/2011 | US20110123637 Protamine/rna nanoparticles for immunostimulation |
| 05/26/2011 | US20110123632 Nanoscale Adjuvants and Related Pharmaceutical Compositions and Methods |
| 05/26/2011 | US20110123629 Targeting of innate immune response to tumor site |
| 05/26/2011 | US20110123624 Formulations comprising aminosterols |
| 05/26/2011 | US20110123620 Silicon dioxide nanoparticles and the use thereof for vaccination |
| 05/26/2011 | US20110123619 Buccal delivery system |
| 05/26/2011 | US20110123611 Peptidyl diacylglycerides |
| 05/26/2011 | US20110123603 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
| 05/26/2011 | US20110123601 Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery |
| 05/26/2011 | US20110123596 Silica sol material having at least one therapeutically active substance for producing biologically degradable and/or resorbable silica gel materials for human medicine and/or medical technology |
| 05/26/2011 | US20110123591 Tumoricidal, bactericidal, or viricidal macrophage activation |
| 05/26/2011 | US20110123571 Use of bacterium for manufacture of a vaccine |
| 05/26/2011 | US20110123570 Actinobacillus suis antigens |
| 05/26/2011 | US20110123569 Vaccine directed against adenovirus serotype 14 |
| 05/26/2011 | US20110123568 Novel use |
| 05/26/2011 | US20110123567 Recombinant rift valley fever (rvf) viruses and methods of use |
| 05/26/2011 | US20110123566 Endogenous adjuvant molecules and uses thereof |
| 05/26/2011 | US20110123565 Structural Proteins of Fish Pancreatic Disease Virus and Uses Thereof |
| 05/26/2011 | US20110123564 Adenoviral-based vectors |
| 05/26/2011 | US20110123561 Methods and compositions for induction or promotion of immune tolerance |
| 05/26/2011 | US20110123560 Infectious Bursal Disease Virus Antigenic Isolates And Vaccines |
| 05/26/2011 | US20110123559 Swine influenza hemagglutinin variants |
| 05/26/2011 | US20110123558 Peptide with Reduced Dimer Formation |
| 05/26/2011 | US20110123557 Anti-hmga1 monoclonal antibodies, process for their preparation and their use for the quantitative determination of hmga1 |
| 05/26/2011 | US20110123556 Immunogen prioritization for vaccine design |
| 05/26/2011 | US20110123555 Preparation and utility of ccr5 inhibitors |
| 05/26/2011 | US20110123554 Uses of immunoconjugates targeting cd138 |
| 05/26/2011 | US20110123553 Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination |
| 05/26/2011 | US20110123552 Agonistic binding molecules to the human OX40 receptor |
| 05/26/2011 | US20110123551 Hvem/btla, hvem/cd 160 and hvem/gd cis complexes and methods of use |
| 05/26/2011 | US20110123550 Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers |
| 05/26/2011 | US20110123549 Antibodies to EphA3 |
| 05/26/2011 | US20110123548 Compositions and methods for the treatment and diagnosis of immune disorders |
| 05/26/2011 | US20110123547 Compounds Having CRTH2 Antagonist Activity |
| 05/26/2011 | US20110123546 Compositions Comprising Antibodies or Antibody Fragments |
| 05/26/2011 | US20110123545 Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases |
| 05/26/2011 | US20110123544 Human antibodies that bind human il-12 and methods for producing |
| 05/26/2011 | US20110123543 TNFalpha antagonists and methotrexate in the treatment of TNF-mediated disease |
| 05/26/2011 | US20110123542 Ccl20-specific antibodies for cancer therapy |
| 05/26/2011 | US20110123541 Human Monoclonal Nicotine Specific Antibodies |
| 05/26/2011 | US20110123540 Potent mucosal immune response induced by modified immunomodulatory oligonucleotides |
| 05/26/2011 | US20110123539 Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer |
| 05/26/2011 | US20110123538 Composition comprising expression or activity inhibitors of ninjurin 1 for the prevention and treatment of inflammatory disease |
| 05/26/2011 | US20110123537 Binding epitopes for g250 antibody |
| 05/26/2011 | US20110123536 Novel human anti-r7v antibodies and uses thereof |
| 05/26/2011 | US20110123535 Use of Nogo Receptor-1 (NGR1) for Promoting Oligodendrocyte Survival |
| 05/26/2011 | US20110123534 Novel compounds for modulating neovascularisation and methods of treatment using these compounds |
| 05/26/2011 | US20110123533 Using EGFRvIII to Identify and Target Cancer Stem Cells |
| 05/26/2011 | US20110123532 Method for Making Heteromultimeric Molecules |
| 05/26/2011 | US20110123531 Combination therapy |
| 05/26/2011 | US20110123530 Compositions and methods for treating and diagnosing asthma |
| 05/26/2011 | US20110123529 Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
| 05/26/2011 | US20110123528 Humanized anti-factor d antibodies and uses thereof |
| 05/26/2011 | US20110123527 Method of generating single vl domain antibodies in transgenic animals |
| 05/26/2011 | US20110123526 Methods and compositions for preventing adhesion |
| 05/26/2011 | US20110123525 Anti-angiogenic therapy |
| 05/26/2011 | US20110123524 Methods for treating hematopoietic malignancies |
| 05/26/2011 | US20110123523 Antibodies against erbb3 and uses thereof |
| 05/26/2011 | US20110123522 Methods of treating cancer using anti cd24 antibodies |
| 05/26/2011 | US20110123521 Methods for modulating expression of rbp4 |
| 05/26/2011 | US20110123520 Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| 05/26/2011 | US20110123519 Recombinant antigen |
| 05/26/2011 | US20110123518 Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid |
| 05/26/2011 | US20110123496 Bismacrocyclic compounds as hepatitis c virus inhibitors |
| 05/26/2011 | US20110123494 Treatment with anti-vegf antibodies |
| 05/26/2011 | US20110123492 Immunity-inducing agent |
| 05/26/2011 | US20110123491 Methods and compositions for immunization against chlamydial infection and disease |
| 05/26/2011 | US20110123490 Heterocyclic antiviral compounds |
| 05/26/2011 | US20110123486 Methods of treating multiple myeloma and resistant cancers |
| 05/26/2011 | US20110123485 Viral vectors for delivering vaccines for hiv and other infectious diseases |
| 05/26/2011 | US20110123454 Method for modulating appetite |
| 05/26/2011 | US20110123451 Method for Cell Delivery Using Targeted Liposomes Associated with a Hemolysin |
| 05/26/2011 | US20110123447 Method of providing human tumor-specific antibodies |
| 05/26/2011 | US20110123446 Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates |
| 05/26/2011 | US20110123442 Tumor specific antibodies and uses therefor |
| 05/26/2011 | US20110123441 Novel greb1a monoclonal antibody |
| 05/26/2011 | US20110123440 Altered Antibody FC Regions and Uses Thereof |
| 05/26/2011 | US20110123438 Universal anchor peptide for nanoparticles |
| 05/26/2011 | US20110123436 Dock-and-Lock (DNL) Complexes for Delivery of Interference RNA |
| 05/26/2011 | US20110123435 Compounds for inhibiting ksp kinesin activity |
| 05/26/2011 | US20110123434 Combination therapies comprising quinoxaline inhibitors of p13k-alpha for use in the treatment of cancer |
| 05/26/2011 | CA2818237A1 Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| 05/26/2011 | CA2785376A1 Pharmaceutical composition |
| 05/26/2011 | CA2781532A1 Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1 |
| 05/26/2011 | CA2781467A1 Formulations of antibody |
| 05/26/2011 | CA2781397A1 Compositions, methods and uses for poxvirus elements in vaccine constructs |
| 05/26/2011 | CA2781290A1 Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr) |
| 05/26/2011 | CA2781032A1 Ifny inhibitors in the treatment of motoneuron diseases |
| 05/26/2011 | CA2781019A1 Display of disulfide linked dimeric proteins on filamentous phage |
| 05/26/2011 | CA2780487A1 Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
| 05/26/2011 | CA2780207A1 Low antigen-dose immunization for maximizing t-helper cell 1 (th1) immunity against disease |
| 05/26/2011 | CA2778864A1 Humanized antibodies against human il-22ra |